Prof. Dr. Georg Schett is a leading expert in rheumatology and immunology, serving as Vice President Research at Friedrich-Alexander-Universität Erlangen-Nürnberg, contributing to significant advancements in understanding and treating immune-inflammatory diseases.
As Vice President Research, Professor Schett is mainly responsible for FAU's research strategy, research infrastructure, and research funding.
Expanded research partnership includes a 3-year longitudinal biomarker collaboration exploring the mode of action of autologous CD19 CAR T-cell therapy. Professor Schett also joined Kyverna Therapeutics' Scientific Advisory Board.
Ahead Therapeutics reached an agreement with Prof. Dr. med.-univ. Schett from University Erlangen-Nürnberg to advance in the preclinical development of AT_1001.
RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure major autoimmune diseases. Professor Schett's expertise is valued in this field.
The DFG funds several of Prof. Schett's projects, including the IMMUNOBONE priority program and the collaborative research centre 1181 "Checkpoints for Resolution of Inflammation." He also received the 2023 "Funding Prize in the Gottfried Wilhelm Leibniz Programme" from the DFG.
Prof. Schett is involved in projects funded by Horizon 2020.
Prof. Schett received an ERC-Synergy grant “4D+ nanoSCOPE” for his work.
Prof. Schett is spokesperson of the project METARTHROS, funded by the Federal Ministry of Education and Research, which investigates the impact of the metabolism on arthritis.
Prof. Dr. Georg Schett graduated from the University of Innsbruck, Austria, in 1994. Following his medical degree, he began his scientific career at the Institute of BioMedical Aging Research in Innsbruck. Two years later, he joined the Department of Medicine at the University of Vienna, where he completed his postgraduate training in Internal Medicine and then specialized in Rheumatology. In 2003, he was promoted to professor of Internal Medicine. Before assuming his current position, Professor Schett spent a year in the United States as a scientist.
Since 2006, Prof. Dr. Schett has been the head of the Department of Medicine 3 — Rheumatology and Immunology at Uniklinikum Erlangen, part of the Friedrich-Alexander-Universität Erlangen-Nürnberg in Germany. His scientific work encompasses a broad range of clinical and immunological topics, with a particular focus on the molecular underpinnings of immune-inflammatory diseases. Early in his career, he investigated the immunology of atherosclerosis and antibody-mediated endothelial cell damage. His research led to a better understanding of LE-cells in 2007. In 2008, he co-initiated the IMMUNOBONE priority program in Germany, funded by the German Research Foundation (DFG), aimed at exploring the interactions between skeletal and immune systems. Since 2015, he has led the DFG collaborative research centre 1181 “Checkpoints for Resolution of Inflammation” in Erlangen. He is also the spokesperson for the METARTHROS project, funded by the Federal Ministry of Education and Research, which examines the impact of metabolism on arthritis.
In 2019, Prof. Schett received funding for the ERC-Synergy grant “4D+ nanoSCOPE,” for which he serves as spokesperson. This project focuses on developing tools and techniques for time-resolved imaging and characterization of bone in three spatial dimensions, both in vitro and in vivo. This work aims to monitor bone remodeling and revolutionize the understanding of bone morphology and function. In 2021, he was appointed Vice President for Research at the Friedrich-Alexander-Universität Erlangen-Nürnberg and became a Leopoldina member of the German National Academy of Sciences. He has published over 1100 peer-reviewed papers and received numerous accolades, including the Carol-Nachman Prize and the 2023 “Funding Prize in the Gottfried Wilhelm Leibniz Programme” from the DFG.
Curious about our offerings or have inquiries? We're eager to assist!
Just complete the form, and we'll respond promptly.